Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Comparison of FCSEMS and Plastic Stents (WON-MVP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02685865
Recruitment Status : Completed
First Posted : February 19, 2016
Last Update Posted : February 11, 2019
Sponsor:
Information provided by (Responsible Party):
Florida Hospital

Brief Summary:
The research design is a randomized prospective clinical trial comparing Endoscopic ultrasound (EUS) guided drainage of WON using FCSEMS and plastic stents. The trial will be conducted at the Florida Hospital Center for Interventional Endoscopy, Orlando, Florida.

Condition or disease Intervention/treatment Phase
Infected Pancreatic Necrosis Acute Pancreatic Fluid Collection Pancreatic and Peripancreatic Necrosis Pancreatic Collection Symptomatic Pancreatic Necrosis Device: FCSEM Stent Device: Plastic Stent Not Applicable

Detailed Description:
The research design is a randomized prospective clinical trial comparing EUS-guided drainage of WON using FCSEMS and plastic stents. The trial will be conducted at the Florida Hospital Center for Interventional Endoscopy, Orlando, Florida.The sample size estimated for this study is 60 patients. All patients will undergo EUS-guided drainage of WON and be randomized to either FCSEM or plastic stents in a 1:1 ratio using a computer-generated randomized sequence. It will not be possible to blind the endoscopist to the stent type being inserted due to the differences in stent appearance. The statistician will be blinded to the stent type utilized.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Randomized Trial Comparing Fully Covered, Self-Expanding Metal Stent and Plastic Stents for Endoscopic Ultrasound-guided Drainage of Walled-off Necrosis
Actual Study Start Date : February 12, 2016
Actual Primary Completion Date : July 10, 2018
Actual Study Completion Date : August 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Active Comparator: FCSEM Stent
WON is first identified using EUS and punctured using a 19 gauge needle. 10 ml of fluid is aspirated and sent for gram stain and culture with sensitivities. Using a catheter-based stent delivery system with a 15mm AXIOS stent mounted onto it is inserted into the echoendoscope, and introduced into the WON cavity so that the stent lies within both the WON and enteric lumen. The stent is then deployed so that one flange of the stent is located within the WON cavity and the other flange is located within the enteric lumen.
Device: FCSEM Stent
Hot Axios Fully covered self-expandable metal stent - Boston Scientific
Other Name: Fully covered self-expandable metal stent

Active Comparator: Plastic Stents
WON is first identified using EUS, and punctured using a 19 gauge needle. 10 ml of the WON fluid is aspirated and sent for gram stain and culture with sensitivities. A 0.025 or 0.035 inch guidewire is inserted into the WON through the fine needle aspiration (FNA) needle. A transmural tract is created using an Endoscopic Retrograde Cholangiopancreatography(ERCP) catheter (with the use of a needle knife catheter ± cautery if needed), and then dilated using a 12-13.5-15mm Controlled Radial Expansion (CRE) balloon to a maximum size of 15mm if technically possible. Two or three 7 French plastic stents are inserted through the transmural tract into the WON cavity.
Device: Plastic Stent
7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific




Primary Outcome Measures :
  1. The number of interventions performed between metal and plastic stent groups to achieve treatment success [ Time Frame: 6 weeks ]
    The primary objective of this study is to compare the number of interventions performed between metal and plastic stent groups to achieve treatment success at 6 week follow-up. Re-intervention is defined as the need for repeat EUS-guided drainage of WON using the same stent type and/or DEN and/or insertion of percutaneous catheter due to inadequate treatment response following initial WON drainage. As FCSEMS have larger diameter than plastic stents, the investigators hypothesize that the no. of re-interventions performed will be lower in the FCSEMS group compared to the plastic stent group.


Secondary Outcome Measures :
  1. Technical success [ Time Frame: at index treatment Day 0 ]
    Successful deployment of transmural stents in to the WON cavity.

  2. Treatment success [ Time Frame: 6 week ]
    Resolution of WON on CT scan and resolution of symptoms at 6-week outpatient follow-up (from day of hospital discharge) WITHOUT the need for cross-over to minimally invasive surgical debridement

  3. Treatment failure [ Time Frame: 6 months ]
    Need for minimally-invasive surgical debridement as a consequence of inadequate endoscopic treatment response, or death as a direct consequence of WON drainage or underlying diseaseor underlying disease.

  4. Recurrence [ Time Frame: 6 months ]
    Development of WON or additional Pancreatic Fluid Collection and recurrence of symptoms following initial treatment success

  5. Procedure duration (minutes) [ Time Frame: at index treatment Day 0 ]
    Time from start of the procedure (endoscope inserted into the gastrointestinal lumen to perform transmural drainage to the end of the procedure (removal of the echoendoscope/ gastroscope/ duodenoscope from the oropharynx).

  6. Adverse events [ Time Frame: 6 months ]
    Adverse event directly resulting from performing endoscopic drainage procedure. The severity will be graded according to a previously published consensus.

  7. Duration of hospitalization [ Time Frame: 6 months ]
    Day of procedure to the day of hospital discharge

  8. Cost Analysis (Inpatient and outpatient costs) [ Time Frame: 6 months ]
    Inpatient and outpatient costs of care will be calculated based on Medicare reimbursement fee structure.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject (or when applicable the subject's LAR) is capable of understanding and complying with protocol requirements.
  2. The subject (or when applicable the subject's LAR) is able to understand and willing to sign an informed consent form prior to the initiation of any study procedures.
  3. Males or females ≥ 18 years of age.
  4. WON diagnosed on contrast-enhanced dual phase CT abdomen/pelvis (CECT) or MRI with gadolinium (seen as a fluid collection in the setting of documented pancreatic necrosis that contains necrotic material and encased within a well-defined tissue layer).
  5. WON of any size with any quantity of solid/necrotic component and any no. of loculations, located within the pancreatic/peri-pancreatic space not requiring percutaneous drainage, within 2cm of the enteric wall
  6. Suspected/confirmed infected WON (defined as temp ≥ 100.5°F, serum White Blood Cells ≥ 15x109/L, positive blood cultures or positive Gram stain/culture of aspirated necrotic material), and/or symptomatic WON (defined as abdominal pain, gastric/intestinal/biliary outlet obstruction resulting in nausea, vomiting, early satiety, jaundice, or persistent malaise) ≥ 4 weeks from attack of acute pancreatitis.
  7. Documented history of acute or chronic pancreatitis:

    i. Acute pancreatitis is diagnosed if 2 of the following 3 criteria are met:

    1. Abdominal pain characteristic of acute pancreatitis
    2. Serum lipase/amylase ≥ x3 upper limit of normal
    3. Characteristic radiological findings of acute pancreatitis on CECT/MRI/US abdomen, such as homogeneous enhancement of pancreatic parenchyma, standing of peripancreatic fat ii. Chronic pancreatitis is diagnosed if characteristic radiological changes are seen on CT/MRI with Magnetic resonance cholangiopancreatography (MRCP) (such as pancreatic atrophy, dilated pancreatic duct, pancreatic calcification) or EUS (≥5/9 of Rosement criteria)
  8. Able to undergo general anesthesia

Exclusion Criteria:

  1. Females who are pregnant or lactating. Pregnancy for females of childbearing potential will be determined by routine preoperative urine or serum Human Chorionic Gonadotropin testing.
  2. Irreversible coagulopathy (INR >1.5, thrombocytopenia with platelet count <50,000/mL)
  3. Has surgically altered gastrointestinal anatomy such as but not limited to Billroth II, Roux-en-Y, gastric bypass
  4. Age < 18 years
  5. Unable to obtain consent for the procedure from either the patient or LAR
  6. Use of anticoagulants that cannot be discontinued for the procedure
  7. Unable to tolerate general anesthesia
  8. WON that is not accessible for EUS-guided drainage
  9. Percutaneous drainage of WON is required or performed prior to EUS-guided drainage

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02685865


Locations
Layout table for location information
United States, Florida
Center for Interventional Endoscopy - Florida Hospital Orlando
Orlando, Florida, United States, 32803
Florida Hospital Center for Interventional Endoscopy
Orlando, Florida, United States, 32803
Sponsors and Collaborators
Florida Hospital
Investigators
Layout table for investigator information
Principal Investigator: Shyam Varadarajulu, MD Florida Hospital Orlando

Publications:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Florida Hospital
ClinicalTrials.gov Identifier: NCT02685865    
Other Study ID Numbers: 837579
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: February 11, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Florida Hospital:
pancreatic fluid collection; pancreatic necrosis; stent;
Additional relevant MeSH terms:
Layout table for MeSH terms
Necrosis
Pathologic Processes